Simplicity Wealth LLC Raises Holdings in Ocular Therapeutix, Inc. $OCUL

Simplicity Wealth LLC increased its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 44.1% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 40,332 shares of the biopharmaceutical company’s stock after buying an additional 12,345 shares during the period. Simplicity Wealth LLC’s holdings in Ocular Therapeutix were worth $374,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. Brooklyn Investment Group raised its stake in Ocular Therapeutix by 151.5% in the first quarter. Brooklyn Investment Group now owns 5,238 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 3,155 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Ocular Therapeutix by 17.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,154 shares of the biopharmaceutical company’s stock worth $57,000 after buying an additional 893 shares in the last quarter. GAMMA Investing LLC raised its stake in Ocular Therapeutix by 6,760.0% in the first quarter. GAMMA Investing LLC now owns 8,232 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 8,112 shares in the last quarter. Trust Co. of Vermont raised its stake in Ocular Therapeutix by 16.1% in the second quarter. Trust Co. of Vermont now owns 7,200 shares of the biopharmaceutical company’s stock worth $67,000 after buying an additional 1,000 shares in the last quarter. Finally, Vontobel Holding Ltd. bought a new position in Ocular Therapeutix in the first quarter worth approximately $79,000. Institutional investors own 59.21% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Zacks Research raised shares of Ocular Therapeutix from a “strong sell” rating to a “hold” rating in a research note on Thursday, October 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ocular Therapeutix in a report on Wednesday. Chardan Capital reaffirmed a “buy” rating and issued a $21.00 price target on shares of Ocular Therapeutix in a report on Thursday, October 2nd. Scotiabank cut their price target on shares of Ocular Therapeutix from $22.00 to $20.00 and set a “sector outperform” rating on the stock in a report on Wednesday, August 6th. Finally, HC Wainwright lifted their price target on shares of Ocular Therapeutix from $15.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $22.63.

Insider Transactions at Ocular Therapeutix

In other news, insider Jeffrey S. Heier sold 10,502 shares of Ocular Therapeutix stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $11.04, for a total transaction of $115,942.08. Following the completion of the sale, the insider directly owned 249,409 shares in the company, valued at approximately $2,753,475.36. The trade was a 4.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Pravin Dugel sold 21,494 shares of Ocular Therapeutix stock in a transaction on Monday, August 25th. The stock was sold at an average price of $12.04, for a total transaction of $258,787.76. Following the sale, the insider owned 3,227,244 shares of the company’s stock, valued at $38,856,017.76. The trade was a 0.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,674 shares of company stock worth $590,279. Company insiders own 2.30% of the company’s stock.

Ocular Therapeutix Trading Up 3.4%

NASDAQ:OCUL opened at $11.91 on Thursday. Ocular Therapeutix, Inc. has a 12 month low of $5.78 and a 12 month high of $13.85. The firm has a fifty day simple moving average of $12.28 and a 200-day simple moving average of $9.80. The company has a current ratio of 10.10, a quick ratio of 10.02 and a debt-to-equity ratio of 0.23. The company has a market capitalization of $2.07 billion, a P/E ratio of -9.30 and a beta of 1.45.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.04). Ocular Therapeutix had a negative return on equity of 71.92% and a negative net margin of 382.51%.The company had revenue of $13.46 million for the quarter, compared to analyst estimates of $13.12 million. During the same quarter in the previous year, the firm posted ($0.26) earnings per share. The company’s quarterly revenue was down 17.7% on a year-over-year basis. On average, equities research analysts anticipate that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current year.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.